Moderna’s COVID-19 vaccine shows promise in first published results

An experimental COVID-19 vaccine from the biotech company Moderna showed promising results in an early trial of 45 participants, according to the first trial data from the company to be published in a peer-reviewed journal.

After receiving two doses of the vaccine, called mRNA-1273, all participants developed so-called neutralizing antibodies, which can block the new coronavirus from infecting cells. The levels of these antibodies in participants’ blood were above the average levels seen in recovered COVID-19 patients, according to the study, published Tuesday (July 14) in The New England Journal of Medicine.

Leave a Reply

Your email address will not be published. Required fields are marked *